Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644875 | 0.94 | SMN1; SMN2 (0.47) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2643760 | 0.94 | WNT3A (0.42) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2643847 | 0.93 | MEN1 (0.47) | MAPTALDH1A1SMN1; SMN2NPC1MEN1 | |
| SCHEMBL2643961 | 0.93 | HTT (0.46) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2643303 | 0.92 | MEN1 (0.36) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2643593 | 0.92 | MAPT (0.40) | MAPTALDH1A1KDM4EHTTGAA | |
| SCHEMBL2643590 | 0.92 | MAPT (0.40) | MAPTALDH1A1KDM4EHTTGAA | |
| SCHEMBL2644105 | 0.91 | MAPT (0.46) | MAPTALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2644546 | 0.91 | WNT3A (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL2664043 | 0.91 | MAPT (0.40) | MAPTALDH1A1KDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | claimed |
| CN-101316836-A | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | CN | claimed |
| EP-1960385-A1 | SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-27 | — | — | EP | claimed |
| WO-2007053503-A1 | SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| CN-101316836-A | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | CN | disclosed |
| EP-1960385-A1 | SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007053503-A1 | SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | MAPT 3322/4885ALDH1A1 1552/4885KDM4E 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.